- 1 **RVOT** Reconstruction in d-Transposition of the Great Arteries with Ventricular Septal
- 2 Defect and Pulmonary Obstruction: Male-Female Differences in Clinical and
- 3 **Homograft Function**
- Xu. Wang, MD¹†, Isabelle M. Bennink, Bsc¹†, Kevin M. Veen, MD, PhD¹, Pieter C. van de 4
- Woestijne, MD¹, Carlijn C. E. M. van der Ven, Bsc¹, Ad J. J. C. Bogers, MD, PhD¹, Eleni-5
- Rosalina Andrinopoulou, PhD^{2,3}, Wim. A. Helbing, MD, PhD⁴, Johanna J.M. Takkenberg, 6
- MD, PhD¹ 7
- ¹ Department of Cardiothoracic Surgery, Erasmus University Medical Center Rotterdam, 8
- 9 Rotterdam, The Netherlands.
- ²Department of Biostatistics, Erasmus University Medical Center Rotterdam, Rotterdam, 10
- 11 The Netherlands.
- ³Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, 12
- The Netherlands. 13
- ⁴ Department of Pediatric Cardiology, Erasmus University Medical Center Rotterdam, 14
- 15 Rotterdam, The Netherlands.
- 16 † These two authors contributed equally to this paper
- **Address for correspondence:** 17
- *Corresponding author: Johanna J.M. Takkenberg, MD, PhD. 18
- 19 Department of Cardiothoracic Surgery, Erasmus University Medical Center, Room Rg-633,
- PO Box 2040, 3000 CA Rotterdam, The Netherlands. 20
- 21 Tel: +31-10-7035413;
- Email: j.j.m.takkenberg@erasmusmc.nl 22
- METC approval: MEC-2012-477 23

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

ABSTRACT Background This study investigated male-female differences in clinical and homograft outcomes in dextro-transposition of the great arteries (d-TGA) patients, with ventricular septal defect (VSD) and pulmonary stenosis/atresia (PS/PA), who underwent right ventricular outflow tract (RVOT) reconstruction with a homograft. Methods All d-TGA with VSD and PS/PA patients receiving a homograft for RVOT reconstruction at our center from 1986 to 2021 were included. Time-to-event analyses were used for timerelated clinical outcomes and mixed-effects models to characterize homograft function. **Results** Twenty-four patients (16 males) in whom 38 homografts were implanted over time were included. Median age at the first homograft implantation was 2.56 years [IQR: 1.26-11.31] and 2.06 years [IQR: 1.28-8.13] for males and females. Two early death (both males) and five late deaths (2 males) were observed. Twenty-two RVOT reinterventions (19/3 in males/females) occurred in follow-up (males/females:345.72/173.35 patient-years). The 10year survival probability was 87.5% (95% CI: 67.3-100) for females and 87.1% (95% CI: 71.8-100) for males. Freedom from RVOT reintervention at 10-year was 87.5% (95% CI: 67.3-100) for females and 64.9% (95% CI: 47.9-88.0) for males. RVOT peak gradient increase rate was associated with body growth rate (7.27 [95% CI: 2.08-12.45], P=0.0133). **Conclusions** Substantial male-female differences in clinical and homograft outcomes were found in d-

TGA with VSD and PS/PA patients receiving a homograft for RVOT reconstruction. Male

patients had a higher RVOT reintervention rate and faster progression to homograft stenotic

- 48 failure compared to females. Oversized homografts might benefit children for the strong
- 49 association between rates of homograft stenosis and body growth.
- Keywords: Transposition of the great arteries, male-female differences, homograft, right 50
- ventricular outflow tract 51

Clinical Perspective

1. What is new?

 Male patients diagnosed with d-TGA, VSD, and PS/PA demonstrated a significantly higher rate of RVOT homograft reinterventions and a more rapid progression toward

homograft stenotic failure when compared with their female counterparts.

- The male-female differences in clinical outcomes and homograft function may be attributed, in part, to the faster body growth observed in male children, especially given the strong association between rates of homograft stenosis and body growth.
- 2. What are the clinical implications?
- For rapidly growing young children, opting for a suitably oversized homograft might serve as a more effective solution in reducing the rate of homograft stenotic failure.
- By exploring the relationship between homograft stenosis rate and individual body
 growth rate for each child, a personalized approach can be adopted during the
 homograft selection process, optimizing the sizing strategy for a better clinical
 outcome.

INTRODUCTION

Dextro-transposition of the great arteries(d-TGA) with ventricular septal defect (VSD) and pulmonary stenosis (PS) or pulmonary atresia (PA) is a rare congenital heart defect (CHD) that requires early palliative or corrective operations to enable patients' survival¹. Despite various corrective options available, dysfunction of the right ventricular outflow tract (RVOT) conduit is almost inevitable during a patient's lifetime². If feasible, implantation of a valve substitute with a homograft is the preferred choice to address this issue³. As most patients received their first homograft as a RVOT conduit during childhood, a period of rapid body growth and development, the homograft function evolution differs from that observed in adults⁴. Additionally, considering the distinct growth patterns between boys and girls⁵, there may be male-female differences in clinical outcomes and homograft function in d-TGA, VSD, PS/PA patients who received homograft as a RVOT conduit during childhood.

Despite the importance of studying this patient group, limited research has been done on these patients, particularly in terms of sex-specific outcomes. Thus, this study aimed to explore male-female differences in clinical outcomes and homograft function after homograft RVOT reconstruction in patients diagnosed with d-TGA, VSD, PS/PA.

PATIENTS AND METHODS

This is a retrospective single-center study. The medical ethics committee (METC) of the Erasmus University Medical Center reviewed and approved this study (MEC-2012-477). Informed consent was obtained from all participants alive. No consent from deceased patients was necessary according to the medical ethics regulations of our medical center.

1. Study population

All d-TGA patients who underwent RVOT reconstruction with a homograft at Erasmus University Medical Center from April 1986 to December 2021 were identified.

Patients not surgically corrected, without VSD and PS/PA, or alive but not giving their consents were excluded. Patients who underwent univentricular repair were also excluded.

2. Data collection

Baseline characteristics, perioperative information, clinical outcomes and echocardiographic parameters during follow-up were extracted by reviewing medical records. Events were defined according to the Akins 2008 guidelines ⁶. Early events were defined as all events occurring within the first 30 days after operation. Any events occurring after 30 days postoperative were defined as late events. Structural valve deterioration (SVD) was defined as stenosis or regurgitation relevant to pulmonary valve without diagnosis of endocarditis. The severities of stenosis and regurgitation were classified in compliance with the ESC/EACTS 2021 guidelines⁷. Stenosis was graded as mild (<36mmHg), moderate (36-64mmHg), and severe (>64mmHg). Regurgitation was graded as zero/trace, mild, moderate, and severe.

3. Statistical methods

Continuous data are presented as mean ± standard deviation (normal distribution) or median with interquartile range (IQR) (non-normal distribution). Categorical data are presented as absolute count with percentages. Comparisons among continuous variables were made with the independent samples t-test or Kruskal-Wallis test, as appropriate. Comparisons of categorical data were made with the Chi-square test or Fisher's exact test, as appropriate. The Shapiro-Wilk test and visual inspections were used to test the normality. The adverse event rate (AER) for clinical outcomes was calculated as total number of observed events over time (including repeated events) divided by total patient-years of follow-up. Survival data are presented as Kaplan-Meier estimates with a standard error or in the form of Kaplan-Meier curves. The log-rank test was used to compare survival outcomes in male and female patients. Fine-Gray sub-distribution hazard models were used for competing risk analysis,

with death being the competing event, and the sex-specific cumulative incidence of homograft reintervention and endocarditis was plotted based on the results⁹.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Two echocardiographic parameters were analyzed to assess homograft function, with only sex, time, and their interaction term as covariates to prevent overfitting. The RVOT peak gradient was evaluated using linear mixed-effects models with random intercepts for homografts. The degree of regurgitation was dichotomized as < moderate or ≥moderate and analyzed using logistic mixed-effects models with random intercepts for homografts. In patients younger than 16 years old, the longitudinal evolution of RVOT peak gradient was correlated to the longitudinal evolution of body surface area (BSA) by multivariate (multiple outcomes) mixed modeling10. The correlation between RVOT peak gradient and BSA was taken into account via the random effects of the model, in particular a multivariate normal distribution was assumed for the variance-covariance matrix of the random effects. Additionally, random slopes of BSA and RVOT peak gradient were predicted in their respective linear mixed-effects models, and associations between them were explored in linear regression model. Sensitivity analysis was conducted by temporarily excluding all measurements of one homograft at a time (leave-one-out sensitivity analysis). The estimates and their 95% CIs were visualized respectively for each model parameter. Linear mixedeffects models with the same structure were then constructed, and the results were compared with the full model without any exclusion. A P-value less than 0.05 was considered statistically significant, and no correction for multiple testing was applied. Statistical analyses were performed with R statistical program (R Foundation for Statistical Computing, Version 4.2.2. https://www.R-project.org/).

RESULTS

1. Baseline characteristics and perioperative information

A total of 24 patients (16 males, 8 females), in whom 38 homografts (29 in males, 9 in females) were used for RVOT reconstructions, were included. Patient baseline characteristics are presented in **Table 1**. The perioperative information for each homograft implantation procedures is provided in **Supplementary material Table S1**. Two patients died during hospitalizations (early death) for homograft replacement. Both of them were males: one died of refractory bleeding and hemorrhagic shock 3 days after operation; one died of septic shock 53 days after the operation. No other early endocarditis or reintervention for homograft was observed.

2. Clinical outcomes

The median length of follow-up was 28.71 years (IQR: 7.30-31.57; patient-years: 345.72) in male patients and 26.24 years (IQR: 12.22-31.95; patient-years: 173.35) in female patients. The completeness of follow-up was 95.98 %, calculated by the method proposed by Wu et al. 11. **Figure 1** displays the time slots of key d-TGA-related events in each patient's journey from birth to death or the end of follow-up, separated by sex. These events include d-TGA corrective operation, first RVOT reconstruction with homograft, subsequent RVOT relevant procedures, homograft endocarditis, and mortality or end of follow-up.

2.1 Late mortality

In total, five late deaths (2 males/ 3 females) occurred during follow-up. Reasons for three deaths in females were as follows: death while awaiting surgery for severe homograft stenosis, erysipelas-induced septic shock, and severe arrhythmia, respectively. Two male patients were found dead at home without clear explanations. The AERs of late death are presented in **Table 2**. The Kaplan-Meier estimates of overall survival are shown in **Figure 2**.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

The 5-,10-,15-, and 20-year survival probabilities of male and female patients are presented in Table 3. 2.2 Homograft reintervention During follow-up, 10 patients (8 males/2 females) received 22 reinterventions (7 percutaneous, 15 surgical). Of all reinterventions, 17 were pulmonary valve replacement (3 percutaneous, 14 surgical). The AERs of late reinterventions and replacement male and female patients are presented in Table 2. Most reinterventions were for stenotic SVD, and two homografts were replaced due to endocarditis. Most surgical replacement procedures were performed in male patients (13/14, 92.9%). Details of all reintervention cases are presented in Supplementary material Table S2. The cumulative incidence of RVOT reintervention with death as a competing event was visualized and is presented in Figure 3. Male patients had a significant higher cumulative incidence of RVOT reintervention compared to female patients (Gray's test: P=0.0296). The Kaplan-Meier estimates of freedom from RVOT replacement are shown in Supplementary material Figure S1. The 5-,10-,15-, and 20-year probabilities of freedom from RVOT reintervention and replacement in male and female patients are presented in **Table 3**. Additionally, the Kaplan-Meier estimates of freedom from RVOT percutaneous/surgical reintervention and percutaneous/surgical replacement are shown in Supplementary material Figure S2- S5. 2.3 Endocarditis There were 4 homografts with endocarditis (all males), of which two required surgical homograft replacement. The AERs of endocarditis are presented in **Table 2**. The cumulative incidence of homograft endocarditis with death as the competing event was visualized and is presented in **Figure 4**. The 5-,10-,15-, and 20-year probabilities of freedom from endocarditis are presented in **Table 3**.

3. Homograft function

The study encompassed 257 echocardiographs conducted on 33 homografts implanted in 20 patients(14 males, 6 females). The total echocardiographic follow-up time was 359.41 patient-years, with male patients contributing 264.14 patient-years and female patients contributing 95.27 patient-years. The completeness of echocardiographic follow-up was 83.2 %, calculated by the method proposed by Wu *et al.*¹¹.Three patients moved abroad after the operations and no further echocardiographic information is available.

3.1 Echocardiographic measurements

The evolution of RVOT peak gradient for each included patient was visualized and is presented respectively for male and female patients in Supplementary material Figure S6-S7. Different homografts in the same patient were plotted in the same panel using different lines.

Results of linear mixed-effects models for RVOT peak gradient are shown in Supplementary material Table S3. Male and female patients exhibited different rates of progression to stenosis, with males progressing at a faster rate (p=0.0272). The results of sensitivity analysis are presented in Supplementary material Figure S8, revealing significant disparities between the results of the five leave-one-homograft-out analyses and those of the full model. Results of logistic mixed-effects models for moderate or higher homograft regurgitation are displayed in Supplementary material Table S4, and its sensitivity analysis results are shown in Supplementary material Figure S9. The effect plots of RVOT peak gradient and probability of moderate or higher homograft regurgitation are presented in Figure 5.

3.2 Associations between RVOT peak gradient and BSA in patients younger 16 years

One hundred eighty-seven BSA measurements were collected from 22 patients younger than 16 years when receiving homografts for RVOT reconstruction. Results of linear mixed-effects models for BSA evolution are presented in Supplementary material Table S5.

The results of the two mixed-effects models for longitudinal evolutions of RVOT peak gradient and children's BSA and their correlation matrix of random effects are exhibited in Supplementary material Table S6. The effect plot of BSA increase over time is shown in Supplementary material Figure S10. A faster increase of BSA over age was observed in boys compared to girls. The random slope of RVOT peak gradient over patient's time-varying age was positively correlated to the slope of BSA over patient's time-varying age (R = 0.5621). Furthermore, a linear regression between the increase of RVOT peak gradient and BSA over time revealed BSA growth rate was significantly association with RVOT peak gradient acceleration rate (7.27 [95% CI: 2.08-12.45], P = 0.0133). This association suggests the role of somatic growth in homograft stenotic failure. The effect estimate of BSA over time is presented for a 0.1 unite increase for its small scale.

DISCUSSION

This study focused on male-female differences in clinical outcomes of d-TGA, VSD, PS/PA patients who received a homograft implantation for RVOT reconstruction, and the long-term course of homograft (dys)function. It shows that male patients have a higher rate of RVOT reintervention, especially reoperations, compared to female patients. Furthermore, a more rapid progression of homograft stenosis was observed in male patients, highlighting the significance of considering sex-specific factors when planning treatment and monitoring patient outcomes. On top of that, a strong association between the increase rates of BSA and RVOT peak gradient was found, underlining the necessity of accounting for the accelerated body growth experienced by young children. In light of this strong association, the use of oversized homografts during RVOT reconstruction might offer benefits for children with d-TGA, VSD, PS/PA, especially in younger children and boys, as they grow faster in body size.

Multiple factors may contribute to the observed male-female differences in this study, encompassing both biological (*sex*) factors such as body growth rate and hormonal influences, and socio-cultural (*gender*) aspects like societal norms and roles¹². In order to comprehensively understand and utilize these differences in a clinically meaningful manner, it is essential to examine both sex and gender aspects within the context of clinical outcomes and homograft function.

1. Homograft reintervention

Many studies concentrating on outcomes of patients undergoing homograft replacement have found a higher rate of homograft reinterventions in males¹³⁻¹⁵, which is consistent with findings in this study. Several potential reasons may explain the phenomenon, e.g., anatomy and physiology, hormonal level, body size and growth rate, etc^{16,17}.

Young children are more prone to early homograft degeneration compared to adults, due to prosthesis-patient mismatch developing over time, as a result of somatic growth^{4,18}. In this study, most of the included patients received their first homograft for RVOT reconstructions before the age of 10, during which their body size rapidly increases over time. Consistent with previous research indicating an accelerated growth rate in young boys compared to girls⁵, our study cohort mirrored the same trend. The divergent growth rates may contribute to an increased occurrence of prosthesis-patient mismatch cases in male patients, and consequently, more reinterventions.

Furthermore, the observed male-female differences may be influenced by sex-specific hormones. During puberty, testosterone levels increase substantially in male adolescents, while estrogen levels rise dramatically in female adolescents^{19,20}. Interestingly, these two sex steroid hormones have been found to be correlated with serum calcium levels²¹. Specifically, estrogen has been linked to reducing serum calcium, whereas testosterone has been

associated with its elevation²¹. The potential impact of their regulatory roles on serum calcium could potentially impact the risk of homograft calcifications and degeneration.

On top of the aforementioned biological factors, gender may also contribute to the higher rate of reinterventions in male patients. Children's gender might influence their parents' care-seeking behavior for them, especially in low- and middle- income countries²². This may not directly apply to the current study, given that the Netherlands is a high-income country. Further information regarding patients and their families social-economic status would help validate whether children's gender interacts with family income levels, potentially affecting parents' healthcare-seeking decisions for their children.

Symptoms are an important part of criteria for heart valve reinterventions⁷. As indicated in some clinical research, male and female patients may differ in clinical symptoms, with female patients more likely to experience atypical symptoms²³⁻²⁵. The atypical symptoms might deter doctors from performing potentially necessary reinterventions in female patients, thereby causing a lower rate of reinterventions in female patients compared to male patients.

2. Homograft stenosis

In this study, out of the 22 reintervention cases, 18 were attributed to homograft stenotic failure. The RVOT peak gradient serves as a common echocardiographic parameter for assessing valve stenosis. Its evolution reflects the progression of stenosis. As depicted in **Figure 5**, male patients demonstrated a faster increase rate of RVOT peak gradient, implying a more rapid development of stenosis compared to their female counterparts. As previously discussed, prosthesis-patient mismatch could be a contributing factor to reinterventions for stenosis in young children. The observed faster stenotic development in male patients might be attributed to a higher incidence of prosthesis-patient mismatch in this group, as boys tend to grow faster than girls⁵. Our investigation of the relationship between the evolutions of

BSA and RVOT peak gradient revealed a strong correlation, suggesting that faster BSA increase is correlated with a more rapid progression of RVOT peak gradient. Considering this strong correlation, accounting for children's future body growth may become essential for clinicians, necessitating the consideration of different homograft sizing for boys and girls to provide more patient-specific clinical management.

Echocardiograph is commonly used to measure homograft function. Usually the time interval between two consecutive measurements depends on the decision made by both doctors and patients. As mentioned previously, female patients are inclined to exhibit more atypical symptoms or even remain asymptomatics²³⁻²⁵. On one hand, doctors may feel reluctant to prescribe appropriate treatment/examinations when facing patients with atypical symptoms. On the other hand, patients with non- or atypical-symptoms might be more likely to decline necessary homograft function evaluations, potentially leading to distortions of the observed evolutions of RVOT peak gradient. Consequently, (symptomatic) male patients received more echocardiographic examinations, capturing higher RVOT peak gradient values, which might contribute to the observed accelerated progression of homograft stenosis in male patients compared to their female counterparts.

3. Limitations

First and foremost, a notable limitation of this study is the very small sample size, which may have decreased the statistical power to detect the significant differences of the observation of many important clinical events during the follow-up period. Additionally, the application of complex modeling methods, such as (multivariate) mixed-effects models, in such a small dataset may lead to overfitted estimates, further warranting cautious extrapolation of results to other patients. Additionally, only linear relations between length of follow-up time and repeated measurements (RVOT peak gradient, ≥ moderate or higher pulmonary regurgitation) were taken into account to avoid potential overfitting issue.

However, nonlinear relations between time and longitudinal outcomes are common in clinical research²⁶. It is necessary to account for nonlinearity when larger sample size is available. Furthermore, reinterventions are recurrent events and should be analyzed using recurrent event survival analysis. However, it is not feasible due to the small sample size, and only the first reintervention was considered for survival analysis in this study. It might affect the estimates of reintervention hazard. Lastly, this is a retrospective study, and its inherent limitations also apply for this study²⁷.

Conclusion

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

336

338

In our single-center experience, there are substantial male-female differences in terms of clinical outcomes and homograft function over time in d-TGA, VSD, PS or PA patients who receive homografts for RVOT reconstruction during or after corrective operations. Given the association between the rate of body growth, notably faster in boys, and the progression of homograft stenosis, somatic growth might contribute to the higher reintervention rate in males. To address this, we recommend employing oversized homografts that account for future increases of body size in young patients when their body size can be measured accurately and the (properly) over-sized homograft is available. Furthermore, the oversizing criteria should be established sex-specifically in light of different body growth rates in young female and male patients.

ACKNOWLEDGMENTS

Not applicable

FUNDING STATEMENT

335 None

CONFLICT OF INTEREST STATEMENT

Nothing to declare. 337

AUTHOR CONTRIBUTION STATEMENT

340

341

342

343

344

345

XW: Conceptualization; Data collection and validation; Statistical analyses; Writing and editing. IMB: Conceptualization; Data collection and validation; Statistical analyses; Writing and editing. KMV: Methodological supervision; Results validation; Manuscript review and editing. PCW: Data validation; Manuscript review and editing. CCEMV: Data collection; Manuscript review and editing. AJJCB: Results validation; Manuscript review and editing. WAH: Results validation; Manuscript review and editing. JJMT: Conceptualization; Supervision; Data and results validation; Manuscript review and editing.

346 Table 1: Baseline characteristics of d-TGA patients with VSD, pulmonary stenosis or atresia

Characteristic		Total n = 24	Male patients n = 16	Female patients n = 8	P- value
Age (correction	on), vears	2.21 (1.09, 5.44)	2.31 (1.06, 4.66)	1.80 (1.09, 7.07)	0.928
Age, years § 1 st homograft		2.34 (1.26, 9.17)	2.56 (1.26, 11.31)	2.06 (1.28, 8.13)	0.742
g -, , ,	2 nd homograft	12.75 (8.14, 17.88)	15.11 (7.72, 19.11)	*	
Corrective pr		18 (75.0)	13 (81.3)	5 (62.5)	0.617
homograft, n (%)					
	ograft implantations	, n (%) §	1	'	0.311
_	First	24 (100.0)	16 (100.0)	8 (100.0)	
-	Second	9 (37.5)	8 (50.0)	1 (12.5)	
-	Third	3 (12.5)	3 (18.8)	0 (0.0)	
-	Fourth	2 (8.3)	2 (12.5)	0 (0.0)	
Homograft ty	pe, pulmonary, n (%) §			0.453
	First homograft	11 (45.8)	6 (37.5)	4 (50.0)	
	econd homograft	7 (77.8)	6 (75.0)	1 (100.0)	
	hird homograft	1 (33.3)	1 (33.3)	0 (0.0)	
	ourth homograft	2 (100.0)	2 (100.0)	0 (0.0)	
Homograft di		18.67 ± 3.52	18.69 ± 2.91	18.63 ± 4.75	0.974
BSA, m ² †	,	0.51 (0.41, 1.05)	0.52 (0.42, 1.26)	0.49 (0.39, 0.86)	0.691
BID, mm/m ²	†	34.12 (20.24,	34.12 (16.63,	35.25 (28.22,	0.927
,	1	41.18)	41.18)	40.40)	
Associated an	omalies, n (%)	,	,	,	0.385
- PA		2 (8.3)	2 (12.5)	0 (0.0)	
- ASD		8 (33.3)	3 (18.8)	5 (62.5)	
- DORV		6 (25.0)	2 (12.5)	4 (50.0)	
- PDA		1 (4.2)	0 (0.0)	1 (12.5)	
- Aorta a	nomalies‡	3 (12.5)	1 (6.3)	2 (25.0)	
- DCRV		1 (4.2)	1 (6.3)	0 (0.0)	
- Pulmoi	nary artery anomalies	2 (8.3)	2 (12.5)	0 (0.0)	
- Corona	ry artery anomalies	1 (4.2)	1 (6.3)	0 (0.0)	
- Pulmoi	nary vein anomalies	1 (4.2)	1 (6.3)	0 (0.0)	
- Hypop	lastic RV	1 (4.2)	0 (0.0)	1 (12.5)	
Corrective O ₁	peration, n (%)				1.000
- Rastell	i procedure	20 (83.3)	13 (81.3)	7 (87.5)	
- REV p	rocedure	2 (8.3)	2 (12.5)	0 (0.0)	
- ASO p	rocedure	2 (8.3)	1 (6.2)	1 (12.5)	
Palliative pro	cedures, n (%)				0.587
- No pal	liative procedure	7 (29.2)	6 (37.5)	1 (12.5)	
- BT or I	Modified BT shunt	10 (41.7)	6 (37.5)	4 (50.0)	
- Waters	ton shunt	3 (12.5)	1 (6.3)	2 (25.0)	
- Potts sl	nunt	1 (4.2)	1 (6.3)	0 (0.0)	
- Rashki	nd procedure	6 (25.0)	3 (18.8)	3 (37.5)	
	l aorto-pulmonary	2 (8.3)	1 (6.3)	1 (12.5)	

³⁴⁷ Data are presented as median (IQR) or mean \pm SD. BSA: body surface area; BID: BSA indexed diameter,

³⁴⁸ calculated using homograft diameter divided by BSA; PA: pulmonary atresia; ASD: atrial septal defect; DORV:

³⁴⁹ double outlet right ventricle; PDA: patent ductus arteriosus; DCRV: double-chambered right ventricle; RV:

- 350 Right ventricle; REV procedure: réparation à l'ètage ventriculaire; ASO: arterial switch operation; BT Shunt: 351 Blalock-Taussig shunt; IQR: interquartile range; SD: standard deviation.
- 352 §: the 1st /2nd /3rd homograft here refer to the homograft that patients received during their first/second/third
- 353 RVOT reconstruction with homograft procedures. The sum of all these numbers in each column is the total
- 354 number of RVOT homograft, which is larger than the number of patients since one patient can receive multiple 355 homografts sequentially.
- 356 *: Values here are only about the diameter of the first homograft used for RVOT reconstruction.
- 357 †: BSA and BID are the values measured prior to the operation of the first RVOT reconstruction with a 358 homograft.
- 359 ‡: Aorta anomalies: Aortic Arch Coarctation/hypoplasia/interrupted aortic arch, Overriding Aorta.
- 360 ‡: Only one second homograft in females. Quantiles cannot be computed. 361

Table 2: Number of events and adverse event rates in male and female patients

362

363

		Males (n = 16)		Females (n = 8)		P-values
		N	AER (95%CI)	N	AER (95%CI)	
FUP, years		28.71 (7.30, 31.57)		26.24 (12.22, 31.95)		
Patient-years		345.72		173.35		
Late	All-cause	2	0.58 (0.07-2.09)	3	1.73 (0.36-5.06)	0.207
mortality	-Cardiac	2	0.58 (0.07-2.09)	2	1.15 (0.14-4.17)	0.481
	-Valve-related	2	0.58 (0.07-2.09)	1	0.58 (0.01-3.21)	0.998
Late reinterventions		19	5.50 (3.31-8.58)	3	1.73 (0.36-5.06)	0.049
- Percutaneous		5	1.45 (0.47-3.38)	2	1.15 (0.14-4.17)	0.787
- Surgical		14	4.05 (2.21-6.79)	1	0.58 (0.01-3.21)	0.028
Replacement		16	4.63 (2.65-7.52)	1	0.58 (0.01-3.21)	0.016
- Percutaneous		3	0.87 (0.18-2.54)	0	0 (0-2.13)	0.220
- Surgical		13	3.76 (2.00-6.43)	1	0.58 (0.01-3.21)	0.037
Endocarditis		4	1.16 (0.32-2.97)	0	0 (0-2.13)	0.157
PPMI/ICD		2	0.58 (0.07-2.09)	1	0.58 (0.01-3.21)	0.997

364 365 366 N: number of events; AER: adverse event rate, patient-years divided by number of events; CI: confidence interval; FUP: length of follow-up; PPMI: permeant pacemaker implantation; ICD: Implantable cardioverter defibrillator.

Table 3: Probabilities of cumulative survival, and freedom from homograft reintervention, replacement and endocarditis

367

368

369

370

371

372 373

Event	Sex	5 years	10 years	15 years	20 years
Patients Survival*, %	Female	87.5 (67.3-100)	87.5 (67.3-100)	72.9 (46.8-100)	72.9 (46.8-100)
	Male	87.1 (71.8-100)	87.1 (71.8-100)	87.1 (71.8-100)	87.1 (71.8-100)
Freedom from	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	66.5 (35.2-100)
reintervention†, %	Male	83.4 (69.8-99.7)	64.9 (47.9-88.0)	38.1 (21.7-66.9)	23.8 (9.9-57.1)
- Percutaneous	Female	100 (100-100)	100 (100-100)	100 (100-100)	75.0 (42.6-100)
	Male	100 (100-100)	94.7 (85.2-100)	74.6 (52.6-100)	74.6 (52.6-100)
- Surgical	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	87.5 (67.3-100)
	Male	83.4 (69.8-100)	69.5 (52.9-91.3)	53.8 (36.1-80.2)	27.7(11.5-66.3)
Freedom from	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	87.5 (67.3-100)
replacement†, %	Male	87.5 (75.1-100)	69.0 (52.3-91.1)	47.5 (29.9-75.5)	29.7 (13.1-67.0)
- Percutaneous	Female	100 (100-100)	100 (100-100)	100 (100-100)	100 (100-100)
	Male	100 (100-100)	94.7 (85.2-100)	85.3 (67.6-100)	85.3 (67.6-100)
- Surgical	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	87.5 (67.3-100)
	Male	87.5 (75.1-100)	73.6 (57.5-94.3)	52.3 (34.4-79.6)	26.9 (11.1-65.1)
Freedom from	Female	100 (100-100)	100 (100-100)	100 (100-100)	100 (100-100)
endocarditis†, %	Male	96.0 (88.6-100)	85.3(71.0-100)	85.3(71.0-100)	71.1 (47.5-100)

*: Survival probability was calculated on patient-level. †: Probabilities of freedom from reintervention, replacement, and endocarditis were calculated on homograft-level. All probabilities are presented in the format of absolute percent (95% confidence interval).




Figure 1: Event timelines of patients with d-TGA/VSD and PS or PA. Each point on the xaxis represents one patient. Each horizontal line stands for the time span of on patient from his or her birth to death or the end of the follow-up. Diamonds of different colors represent different events. All events were arranged chronologically, with the corresponding values on y-axis indicating the age of event occurrence. Patient "P5" died 3 days after the last homograft PVR operation. "PVR": pulmonary valve replacement; "Homograft PVR" is a synonym for RVOT reconstruction with homograft.




Figure 2: Kaplan-Meier survival estimates in male and female patients. The number-at-risk is the number of patients at risk at different time points(not the number of homograft). Log-rank test was used here.




Figure 3: Cumulative incidence of receiving RVOT reinterventions in homografts implanted in male and female patients.




Figure 4: Cumulative incidence of homograft endocarditis in male and female patients.




Figure 5: Effect plots of A: RVOT peak gradient change over time in male and female patients; B: probabilities of having moderate or higher pulmonary regurgitation over time in male and female patients.

400

REFERENCES

- Carole AW. Transposition of the Great Arteries. Circulation. 2006;114(24):2699-403
- 404 2709. doi:doi:10.1161/CIRCULATIONAHA.105.592352
- Hornung TS, Derrick GP, Deanfield JE, Redington AN. Transposition complexes in 405
- the adult: a changing perspective. Cardiology Clinics. 2002/08/01/2002;20(3):405-420. 406
- 407 doi:https://doi.org/10.1016/S0733-8651(02)00012-7
- 408 Romeo JLR, Mokhles MM, van de Woestijne P, et al. Long-term clinical outcome
- 409 and echocardiographic function of homografts in the right ventricular outflow tract†. Eur J
- 410 Cardiothorac Surg. Mar 1 2019;55(3):518-526.
- Henaine R, Roubertie F, Vergnat M, Ninet J. Valve replacement in children: a 411
- 412 challenge for a whole life. Arch Cardiovasc Dis. Oct 2012;105(10):517-28.
- 413 Kozieł S. Relationships among tempo of maturation, midparent height, and growth in
- 414 height of adolescent boys and girls. Am J Hum Biol. Jan-Feb 2001;13(1):15-22.
- 415 Akins CW, Miller DC, Turina MI, et al. Guidelines for reporting mortality and 6.
- 416 morbidity after cardiac valve interventions. Ann Thorac Surg. Apr 2008;85(4):1490-5.
- 417 Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the
- 418 management of valvular heart disease. Eur Heart J. Feb 12 2022;43(7):561-632.
- 419 Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact
- 420 test. Restor Dent Endod. May 2017;42(2):152-155.
- 421 Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model
- 422 analyses for competing risk data. Stat Med. Nov 30 2017;36(27):4391-4400.
- 423 Rizopoulos D. The R Package JMbayes for Fitting Joint Models for Longitudinal and
- 424 Time-to-Event Data Using MCMC. Journal of Statistical Software. 2016;72(7):1 - 46.
- 425 doi:10.18637/jss.v072.i07
- 426 Wu Y, Takkenberg JJ, Grunkemeier GL. Measuring follow-up completeness. Ann
- 427 Thorac Surg. Apr 2008;85(4):1155-7.
- 428 Bewley S, McCartney M, Meads C, Rogers A. Sex, gender, and medical data. *Bmj*.
- 429 2021;372:n735. doi:10.1136/bmj.n735
- 430 Oeser C, Uyanik-Uenal K, Kocher A, Laufer G, Andreas M. Long-term performance
- 431 of pulmonary homografts after the Ross procedure: experience up to 25 years. Eur J
- Cardiothorac Surg. May 1 2019;55(5):876-884. 432
- 433 Caldarone CA, McCrindle BW, Van Arsdell GS, et al. Independent factors associated 14.
- 434 with longevity of prosthetic pulmonary valves and valved conduits. J Thorac Cardiovasc
- 435 Surg. Dec 2000;120(6):1022-30; discussion 1031.
- 436 15. Zubairi R, Malik S, Jaquiss RDB, Imamura M, Gossett J, Morrow WR. Risk Factors
- 437 for Prosthesis Failure in Pulmonary Valve Replacement. The Annals of Thoracic Surgery.
- 438 2011/02/01/2011;91(2):561-565. doi:https://doi.org/10.1016/j.athoracsur.2010.07.111
- 439 Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward
- 440 understanding and prevention. Ann Thorac Surg. Mar 2005;79(3):1072-80.
- Jiao L, Machuki JO, Wu Q, et al. Estrogen and calcium handling proteins: new 441
- 442 discoveries and mechanisms in cardiovascular diseases. Am J Physiol Heart Circ Physiol.
- 443 Apr 1 2020;318(4):H820-H829.
- 444 David TE. Aortic Valve Replacement in Children and Young Adults*. Journal of the 18.
- 445 American College of Cardiology. 2016/06/21/2016;67(24):2871-2873.
- 446 doi:https://doi.org/10.1016/j.jacc.2016.04.023
- 447 19. Courant Fdr, Aksglaede L, Antignac J-P, et al. Assessment of Circulating Sex Steroid
- 448 Levels in Prepubertal and Pubertal Boys and Girls by a Novel Ultrasensitive Gas
- 449 Chromatography-Tandem Mass Spectrometry Method. The Journal of Clinical
- 450 Endocrinology & Metabolism. 2010;95(1):82-92. doi:10.1210/jc.2009-1140

- 451 20. Khan L. Puberty: Onset and Progression. *Pediatr Ann.* Apr 1 2019;48(4):e141-e145.
- 452 21. Van Hemelrijck M, Michaelsson K, Nelson WG, et al. Association of serum calcium
- 453 with serum sex steroid hormones in men in NHANES III. Aging Male. Dec 2013;16(4):151-
- 454 8.

- 455 22. Sharif AI, Amy M, Sufang G, Alyssa S, Sheeba H, Paul R. Gender-related differences
- in care-seeking behaviour for newborns: a systematic review of the evidence in South Asia. 456
- 457 BMJ Global Health. 2019;4(3):e001309. doi:10.1136/bmjgh-2018-001309
- 458 Meischke H, Yasui Y, Kuniyuki A, Bowen DJ, Andersen R, Urban N. How women
- 459 label and respond to symptoms of acute myocardial infarction: responses to hypothetical
- 460 symptom scenarios. Heart Lung. Jul-Aug 1999;28(4):261-9.
- Dempsey SJ, Dracup K, Moser DK. Women's decision to seek care for symptoms of 461
- acute myocardial infarction. Heart Lung. Nov-Dec 1995;24(6):444-56. 462
- 463 Davis LL, Mishel M, Moser DK, Esposito N, Lynn MR, Schwartz TA. Thoughts and
- 464 behaviors of women with symptoms of acute coronary syndrome. Heart Lung. Nov-Dec
- 465 2013;42(6):428-35.
- Wang X, Andrinopoulou ER, Veen KM, Bogers A, Takkenberg JJM. Statistical 466
- 467 primer: an introduction to the application of linear mixed-effects models in cardiothoracic
- surgery outcomes research-a case study using homograft pulmonary valve replacement data. 468
- Eur J Cardiothorac Surg. Sep 2 2022;62(4) 469
- 470 27. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials.
- 471 Crit Care Med. Dec 2009;37(12):3114-9.